Jul 29, 2020 / 05:30PM GMT
Operator
Good afternoon, and welcome to the Oncternal Therapeutics KOL Call on Cirmtuzumab for the Treatment of Mantle Cell Lymphoma. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the Oncternal website following the event.
I would now like to turn the call over to your host, Dr. James Breitmeyer, Chief Executive Officer at Oncternal Therapeutics. Please go ahead, Doctor.
James B. Breitmeyer - Oncternal Therapeutics, Inc. - President, CEO & Director
Thank you, Sarah, and welcome, everybody. Thanks for joining us on this call to discuss the current therapeutic landscape for mantle cell lymphoma and the role that Oncternal's drug cirmtuzumab may play as a potential new treatment in that disease. The primary goal of this call is for you to hear from Dr. Michael Wang, a true key opinion leader in the field of hematology, and more specifically, in mantle cell lymphoma.
Next slide, please. As you can see from this agenda, after my opening remarks, I'll turn it over to Dr. Wang to discuss
Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell Transcript
Jul 29, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers